An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
about
Endocannabinoids as Guardians of MetastasisEvidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosisThe Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in ratsImpact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists.An Overview of Products and Bias in ResearchEpidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasonePain management in neurocritical care.Involvement of the endocannabinoid system in osteoarthritis pain.Use of natural compounds in the management of diabetic peripheral neuropathy.Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.Therapeutic potential of cannabinoids in counteracting chemotherapy-induced adverse effects: an exploratory review.Pharmacological options for the management of refractory cancer pain-what is the evidence?Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Cancer pain management in China: current status and practice implications based on the ACHEON survey.Medical cannabis: considerations for the anesthesiologist and pain physician.The dynamic interaction between pain and opioid misuse.Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds.Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.The Use of Medical Marijuana in Cancer.Transmission pathways and mediators as the basis for clinical pharmacology of pain.Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies.Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.Profiles of medicinal cannabis patients attending compassion centers in rhode island.A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.Cannabis and Cannabinoids for Chronic Pain.The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.Palliative and end-of-life care research in Scotland 2006-2015: a systematic scoping review.Problematic Use of Prescription Opioids and Medicinal Cannabis Among Patients Suffering from Chronic Pain.Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test.Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases.Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy.Medicinal herbs in the treatment of neuropathic pain: a review.Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.Emerging Evidence for Cannabis' Role in Opioid Use Disorder
P2860
Q26766163-96DA23FA-2C30-4703-A137-11A0A4666A97Q26770823-C18F8DE4-C3D3-4656-88E3-261D42F7E1F4Q30733453-CD195850-8579-4E20-A0C8-93FBF62E21B4Q34292608-D0EFF65D-1BEC-4AC5-B03E-5BE71454CF40Q34360705-6BA471B4-E9C6-4125-A560-55355C814CF8Q34486429-3866EFE4-0D44-4C69-90C3-2D8EEEBE2F0BQ36594102-3D7A4878-94E5-4730-B3F8-15962F3795F9Q38124745-CA4B1572-04BB-4D58-9162-9B412E5D4517Q38185076-97A609FC-9928-49D9-9430-B1628DA682E7Q38194034-673ABEAF-DA87-482D-8422-002CD671154DQ38212376-7758D31A-65B5-4AB2-9992-EFDDDAC0EB6DQ38287745-D525D1D6-D1FE-4271-83BC-50670FDAF538Q38370071-C5F02892-8D8B-4EF6-8FFB-1E3975C9BE72Q38503842-E9C5A4CA-E592-4D89-833F-7FB83B75B8ACQ38598922-82903843-9CFD-4A69-82EA-A84BA2D7BA7CQ38724380-83015671-5B79-4D88-9EA6-195223EE462AQ38731968-20B3001A-0D4D-4E69-B936-D0FAF1A07B88Q38785676-03B9C78C-E21D-4614-A19F-7B3A09017514Q38840224-02710FEE-A126-42A3-A467-3A5934C987F7Q38842133-B7B832BD-6C16-4020-B4A7-7D969AE1B9B9Q38870522-9C4659A2-32A5-493F-B35E-51E8EC9D2820Q39151736-C9FB03D8-07EA-4956-BC9F-E0514367D54AQ39973284-89852693-B117-4936-AF33-D3A433163EA8Q41350172-4AE7241E-5532-42F1-8259-66C05DCC6E10Q41453985-EF4C2E51-49EA-4778-8553-08871306388FQ43075872-3F905589-E4C7-4CA1-BBE5-12904C689287Q45047828-7044927B-805B-4ECC-88E0-1CB37F671E61Q47709633-8AC7FFBB-138C-44BF-8C54-356E12A71D06Q47798757-9A7A5077-FCA0-4207-9AA7-983413D75B03Q49814346-DE8A706A-8771-42D8-89C9-3A33AC5851A2Q54958903-035A6BEC-8BBB-4296-91E3-DE8F121DE44EQ55333056-278A5873-3152-4276-9949-A29324C5F7E9Q55340197-472E85B4-8168-4B6D-B581-FA1084385698Q55352555-08DFF3FE-2C23-46DC-9246-A9E80E786731Q55397242-C0B085AF-23F8-4DF3-8DA4-74FA3EFD26E3Q58775143-D9FE65D9-4E62-4547-AED0-96DDC893DFAE
P2860
An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
An open-label extension study ...... y to strong opioid analgesics.
@ast
An open-label extension study ...... y to strong opioid analgesics.
@en
An open-label extension study ...... y to strong opioid analgesics.
@nl
type
label
An open-label extension study ...... y to strong opioid analgesics.
@ast
An open-label extension study ...... y to strong opioid analgesics.
@en
An open-label extension study ...... y to strong opioid analgesics.
@nl
prefLabel
An open-label extension study ...... y to strong opioid analgesics.
@ast
An open-label extension study ...... y to strong opioid analgesics.
@en
An open-label extension study ...... y to strong opioid analgesics.
@nl
P2093
P1476
An open-label extension study ...... y to strong opioid analgesics.
@en
P2093
Dominique Lossignol
Jeremy R Johnson
Marie T Fallon
Mary Burnell-Nugent
P304
P356
10.1016/J.JPAINSYMMAN.2012.07.014
P577
2012-11-08T00:00:00Z